ISAK safe, predictable for reducing low amounts of corneal astigmatism


Corneal astigmatism may be reduced or nearly eliminated after intrastromal femtosecond laser astigmatic keratotomy, explains one ophthalmologist.

There are both advantages and disadvantages for using femto­second laser technology to create astigmatic relaxing incisions, noted Dr William W. Culbertson, the Lou Higgins Professor of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, USA.

Positives, negatives of technology

On the negative side, the laser is expensive and intrastromal incisions may interfere with LASIK procedures in the future.

One use of the femtosecond laser, ISAK, is associated with a number of advantages. According to Dr Culbertson, the procedure:

The procedure, however, is presently limited to lower amounts of astigmatism (≤1.25 D) compared with anterior penetrating relaxing incisions; the nomograms are not yet well established and enhancement procedures are less straightforward, he noted.

Prospective study results

Dr Culbertson and his colleagues conducted a prospective study of ISAK that included 15 patients treated with a femtosecond laser platform [IntraLase, Abbott Medical Optics (AMO)] who had undergone a cataract surgery and were pseudophakic with refractive astigmatism (average, 1.12 D) and a later group of 29 cases treated with the another femtosecond laser platform (Catalys Precision Laser System, AMO/OptiMedica) who had naturally occurring topographic astigmatism (average, 1.02 D) treated during cataract surgery.

The IntraLase procedure was much more labour and time intensive than the Catalys procedure, he noted.

The former system's preoperative calculations were made manually using topographic pachymetry to measure the corneal thickness for the depth of the incisions. The intended treatment axes were marked on the cornea preoperatively at the slit lamp to align the intended axis at the laser with the intended axis of the topographic treatment, he explained.

With the latter system, no manual calculations are performed.

With a minimum of 3 months of follow-up, eyes treated with the Intra­Lase platform had a substantial reduction in the existing cylinder by 72% with slight steepening of the spherical equivalent, Dr Culbertson explained. The mean preoperative uncorrected vision was 20/50 and postoperatively 20/25.

"This result was a considerable improvement," he said.

Results in the 29 patients treated with the Catalys platform indicated that there was a 65% reduction of the preoperative cylinder. Most of the patients had less than 0.5 D of residual cylinder. The average deviation from the intended axis of placement was 3.6°.

The mean postoperative uncorrected distance visual acuity was 20/25.

Twenty-seven of the 29 patients had a best spectacle-corrected visual acuity of 20/20 postoperatively. One patient in this group had an increase in astigmatism from 0.63 to 1.12 D with an axis flip.

Additional applications

Other uses for this femtosecond laser technology are pairing of the limbal-relaxing incisions with the main incision and orienting the intended axis to the fiduciary mark, he continued.

Dr Culbertson said he likes to place a small mark intrastromally when implanting a toric lens when he aligns the IOL axis along the preplaced intrastromal marks.

"ISAK is a safe and predictable technique for reducing low amounts of corneal astigmatism," Dr Culbertson concluded. "All patients in the IntraLase group, and 28 of the 29 patients in the Catalys group, did very well with reduction of astigmatism to refractively negligible levels."

Related Videos
Ana Neves, head of global marketing for ZEISS Meditec Ophthalmology
Kasperi Kankare at the iCare booth at ESCRS
Scott D Barnes, MD, CMO of STAAR Surgical
Tomislav Bucalic, head of marketing at Geuder, and David Geuder, member of the executive board and CIO
Thomas Bosshard stands at the Oertli Instruments booth at the ESCRS meeting
Eva Kim, MD, speaks about her presentation on ICL versus CLE at the Women in Ophthalmology Summer Symposium 2023 in Marco Island, Florida.
Trukera Medical rebranding ushers in new era of expansion into cornea market
Related Content
© 2023 MJH Life Sciences

All rights reserved.